Authors: Frías JP, Davies MJ, Rosenstock J, et al.
-2.37% HbA1c reduction (15 mg tirzepatide) vs. -1.86% (1 mg semaglutide)
In this open-label, 40-week, phase 3 trial, 1,879 patients with type 2 diabetes were randomly assigned in a 1:1:1:1 ratio to receive subcutaneous tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg once weekly. The primary endpoint was the change in glycated hemoglobin level from baseline to 40 weeks. All three doses of tirzepatide demonstrated statistically superior reductions in HbA1c and greater reductions in body weight compared to semaglutide 1 mg.
Head-to-head phase 3 trial demonstrating that the dual GIP/GLP-1 receptor co-agonist tirzepatide achieved superior glycemic control and weight reduction compared to semaglutide 1 mg.
* Educational commentary prepared by Peptide Health Digest editors to provide context on study methodology.
Frías JP, Davies MJ, Rosenstock J, et al.
This study record was compiled from public biomedical repositories for educational and informational reference. Peptide Health Digest does not claim authorship of the original investigation.
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor co-agonist demonstrating robust metabolic and body composition changes.
A long-acting glucagon-like peptide-1 (GLP-1) receptor agonist engineered with an albumin-binding fatty acid side chain, heavily researched for glycemic control and weight management.
